VolitionRx posts corporate deck presentation on Nu.Q diagnostics strategy

VolitionRX published a corporate presentation outlining its Nu.Q nucleosome platform across cancer, sepsis, NETosis and veterinary diagnostics.

• The animal-health business cited USD 23 million in licensing revenue and reported USD 1.4 million of revenue in H1 2026.
• The presentation flagged a potential USD 5 million contractual milestone tied to feline use, contingent on publication of a submitted cat paper.
• The sepsis program was positioned for commercial launch in Q3 2026, with reimbursement submission described as in preparation.
• The strategy emphasizes IP out-licensing with milestone payments, component sales and royalties, and cited 74 granted patents with coverage up to 2044.